KMT2C and breast carcinoma: Importantly MLL3 is mutated in a number of solid cancers, including 8%–11% of breast cancers (Ellis et al., 2012, Wang et al., 2011), although a role for MLL3 in breast cancer and the functional consequences of these mutational events are not known.